Polymer Open Access
A polymer is a substance or material comprising of exceptionally huge particles, or macromolecules, made out of many rehashing subunits. Because of their expansive range of properties, both manufactured and common
polymers assume basic and pervasive jobs in way of life.
Polymers go from recognizable manufactured plastics like polystyrene to regular
biopolymers like DNA and proteins that are central to organic structure and execution. Polymers, both characteristic and fake, are made by means of polymerization of the numerous little particles, alluded to as monomers. Their subsequently huge sub-atomic mass, comparative with little particle mixes, produces one of a kind physical properties including strength, high versatility, viscoelasticity, and a twisted to shape indistinct and semicrystalline structures as opposed to precious stones. The expression "polymer" gets from the Greek word πολÏς (polus, signifying "some, much") and μÎρος (meros, signifying "part"), and alludes to enormous
atoms whose structure comprises of various rehashing units, from which starts an attribute of high relative sub-atomic mass and specialist properties. The units forming
polymers infer, really or reasonably, from particles of low relative sub-atomic mass. The term was begat in 1833 by Jöns Jacob Berzelius, however with a definition unmistakable from the in vogue IUPAC definition. The cutting edge idea of
polymers as covalently fortified macromolecular structures was proposed in 1920 by Hermann Staudinger, who spent resulting decade finding test proof for this speculation.
High Impact List of Articles
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Monitoring rules for toxicity in Phase II oncology trials
Anastasia Ivanova, Guochen Song, Olga Marchenko & Stergios Moschos
Clinical Trail Perspective: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
Recombinant factor XIII (rFXIII): a novel treatment of congenital factor XIII deficiency
Aida Inbal
Drug Evaluation: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Edward L Nelson
Clinical Trail Outcomes: Clinical Investigation
-
Treatment of albuminuria due to diabetic nephropathy: recent trial results
Edward J Horwitz & Jeffrey R Schelling
Review: Clinical Trail Outcomes: Clinical Investigation
-
Treatment of albuminuria due to diabetic nephropathy: recent trial results
Edward J Horwitz & Jeffrey R Schelling
Review: Clinical Trail Outcomes: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 6
Acknowledgements: Clinical Investigation
-
Acknowledgements: Clinical Investigation Vol 3, Iss 6
Acknowledgements: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
New developments in the treatment of diabetic macular edema: latest clinical evidence
Shani Golan, Anat Lowenstein
Review: Clinical Trail Outcomes: Clinical Investigation
-
Design of patent foramen ovale closure trials: the importance of patient-reported outcomes
John D Carroll, Bray Patrick-Lake
Clinical Trail Outcomes: Clinical Investigation
-
Design of patent foramen ovale closure trials: the importance of patient-reported outcomes
John D Carroll, Bray Patrick-Lake
Clinical Trail Outcomes: Clinical Investigation
Relevant Topics in Clinical